Ganirelix Acetate
- CAS No.
- 123246-29-7
- Chemical Name:
- Ganirelix Acetate
- Synonyms
- GANIRELIX;Ganirelixum;5-?dihydroxy-;3-?bis[[3-?(3;ganirelix Acetate;Ganirelix DiAcetate;Ganirelix Impurity 1;Ganirelix Acetate API;Ganirelix Acetate USP/EP/BP;4-?dihydroxyphenyl)?-?1-?oxo-?2-?propen-?1-?yl]?oxy]?-?4
- CBNumber:
- CB61370494
- Molecular Formula:
- C80H113ClN18O13
- Molecular Weight:
- 1570.34
- MDL Number:
- MFCD00869671
- MOL File:
- 123246-29-7.mol
Sequence | Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-Tyr-D-Har(Et2)-Leu-Har(Et2)-Pro-DAla-NH2 |
---|---|
FDA UNII | 56U7906FQW |
ATC code | H01CC01 |
Ganirelix Acetate price
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
Usbiological | 278309 | Ganirelix acetate | 123246-29-7 | 5mg | $1133 | 2021-12-16 | Buy |
Usbiological | G2007-25 | Ganirelix | 123246-29-7 | 50ug | $396 | 2021-12-16 | Buy |
American Custom Chemicals Corporation | INJ0005457 | GANIRELIX 95.00% | 123246-29-7 | 50G | $442 | 2021-12-16 | Buy |
American Custom Chemicals Corporation | INJ0005457 | GANIRELIX 95.00% | 123246-29-7 | 150G | $863.24 | 2021-12-16 | Buy |
Apolloscientific | BITH3021 | Ganirelix | 123246-29-7 | 50μg | $216 | 2021-12-16 | Buy |
Ganirelix Acetate Chemical Properties,Uses,Production
Originator
Antagon,Organon
Definition
ChEBI: Ganirelix is a polypeptide.
Manufacturing Process
The abbreviations for common aminoacids are those recommended by IUPACIUB Comission on Biochemical Nomenclature. Other abbreviations useful in
describing the replacements of aminoacids in the natural LH-RH peptide are
following:
Nal(2) - 3-(2-naphthyl)alanyl; p-Cl-Phe - 3-(p-chlorophenyl)alanyl; Pal(3) - 3-
(3-pyridyl)alanyl; ; hArg(Et)2 - NG,NG - bis(ethtyl)homoarginyl; Boc - tbutyloxycarbonyl.
Ganirelix (N-Ac-Nal(2)-D-pCl-Phe-D-Pal(3)-Ser-Tyr-D-hArg(Et)2-Leu-hArg(Et)2-
Pro-Ala-NH2) was prepared using the following side chain protection protocol:
salt protection for L- and D-hArg(Et)2 (as the chloride) and t-butyl protection
for serine.
Amino acids were added to the Nα-Boc-D-Ala-O-Resin (1.0 mmol of resin was
replaced in the reaction vessel of 5.0 L Vega 296 automated solid phase
peptide synthesizer; in the following sequence:
Acetic anhydride
An acetylation (capping of the resin) was done after Ala, Pro and Leu with
N,N'-diisopropyl carbodiimide - 1-hydroxybenztriazole (HBt). Excess HBt (2
equiv.) was used for the coupling of the basic amino acids, hArg(Et)2 and
Pal(3).
The following protocols were used to remove the Nα-protecting group following
each addition.
Program A: The resin was first washed with CH2Cl2 1 times/1 min, TFA-CH2Cl2
(40/60) 1 times/1 min, TFA-CH2Cl2 (40/60) 1 times/30 min, CH2Cl2 2 5
times/1 min, Et3N-CH2Cl2 (5/95) 3 times/1 min, CH2Cl2 4 times/1 min.
Program B: The resin was first washed with CH2Cl2 1 times/1 min, 4-4.5 N
HCl in CH2Cl2/i-PrOH (1/1) 1 times/1 min, 4-4.5 N HCl in CH2Cl2/i-PrOH (1/1)
1 times/30 min, CH2Cl2 3 times/1 min, DMF 1 times/1 min, Et3N-CH2Cl2
(5/95) 3 times/1 min, DMF 1 times/1 min, CH2Cl2 4 times/1 min.
After each deprotecting and washing step, following protocol A or B, the next
amino acid in sequence was added and the resin washed with CH2Cl2 3
times/1 min, MeOH 4 times/1 min, DMF 2 times/1 min and CH2Cl2 4 times/1
min.
Program A was used for the removal of the protecting groups on Ala, Pro, LhArg(Et)2, Leu and D-Nal(2).
Program B was used for the removal of the protecting groups on D-hArg(Et)2,
Tyr, Ser, D-Pal(3) and p-Cl-Phe.
The crude peptide was first dissolved in 2 M acetic acid and converted to its acetate salt by passage through a column of AG3-X4A resin (Bio-Rad). The
acetate was subjected to chromatography on a silica gel column (CH2Cl2/iPrOH/MeOH/H2O/HOAc solvent); the acetate fractions dissolved in H2O and
loaded onto a reversed-phase column (Vydec C-18, 15-20 μ), and purified
using acetonitrile/TEAP (pH 3). Fractions of the desired purity were combined
and diluted with water and reloaded on a reversed-phase HPLC column, then
washed with 1% acetic acid in water. The peptide was stripped with a mixture
of MeOH/CH3CN/HOAc/H2O (44/50/1/5). The residue was dissolved in acetic
acid and precipitated over ether, filtered, washed with ether and dried under
vacuum. Amino acid analyses were performed on a Beckman 119CL amino
acid analyzer. Samples for amino acid analyses were hydrolyzed with 6 N HCl
at 110°C for 20 hrs. Analytical HPLC was performed on a Spectra Physics
8800 chromatograph. Synthesis of ganirelix was confirmed by the presence of
a main peak at rt 18 min; no other peak over 1% was noted at rt 16 min.
Therapeutic Function
LHRH antagonist
Clinical Use
Ganirelix acetate is an analog of GnRH with substitutions at residues 1, 2, 3, 6, 8, and 10. It is not a superagonist but, rather, is a synthetic decapeptide with high antagonist activity and the first GnRH antagonist to be marketed. It is approved for the suppression of LH surges in women who are undergoing ovarian hyperstimulation fertility treatment; LH surges normally promote ovulation. The goal of this drug is to significantly reduce the number of medication days necessary to suppress the LH surge, thereby maintaining eggs in the ovaries. In vitro fertilization (IVF) treatment cycles were historically initiated by the administration of leuprolide acetate to suppress the premature release of LH. This inhibits ovulation so that the eggs remain available for retrieval by a fertility specialist. For this purpose, leuprolide acetate usually is injected for as many as 26 days. Clinical studies have shown that ganirelix acetate can shut down the LH surge in only 5 days of treatment, that the suppression of LH is more pronounced than that of FSH, and that the shorter treatment time minimizes unpleasant side effects, such as hot flashes and headaches.
Ganirelix Acetate Preparation Products And Raw materials
Raw materials
Preparation Products
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
Hebei Guanlang Biotechnology Co,.LTD | +8619930503252 | daisy@crovellbio.com | China | 5828 | 58 |
Zibo Hangyu Biotechnology Development Co., Ltd | +86-0533-2185556 +8617865335152 | Mandy@hangyubiotech.com | China | 10977 | 58 |
Shanghai Affida new material science and technology center | +undefined15081010295 | admin@oudaxin.com | China | 114 | 58 |
hebei hongtan Biotechnology Co., Ltd | +86-86-1913198-3935 +8617331935328 | sales03@chemcn.cn | China | 973 | 58 |
Shaanxi TNJONE Pharmaceutical Co., Ltd | +8618740459177 | sarah@tnjone.com | China | 1143 | 58 |
Alpha Biopharmaceuticals Co., Ltd | +86-15542445688 | sales@alabiochem.com | China | 888 | 58 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21668 | 55 |
Shenzhen Nexconn Pharmatechs Ltd | +86-755-89396905 +86-15013857715 | admin@nexconn.com | China | 10312 | 58 |
Shaanxi Pioneer Biotech Co., Ltd . | +8613259417953 | sales@pioneerbiotech.com | China | 3000 | 58 |
Shanghai Longyu Biotechnology Co., Ltd. | +8619521488211 | info@longyupharma.com | China | 2534 | 58 |
View Lastest Price from Ganirelix Acetate manufacturers
Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
---|---|---|---|---|---|---|---|---|
![]() |
2024-08-21 | Ganirelix Acetate
123246-29-7
|
US $30.00 / box | 1box | 98% | 2000kg | hebei hongtan Biotechnology Co., Ltd | |
![]() |
2024-08-07 | Ganirelix Acetate
123246-29-7
|
US $0.00-0.00 / box | 1box | 99 | 10 tons | Shanghai Affida new material science and technology center | |
![]() |
2024-08-01 | Ganirelix
123246-29-7
|
US $10.00 / kg | 1kg | 98% | 10 ton | Hebei Guanlang Biotechnology Co,.LTD |
-
- Ganirelix Acetate
123246-29-7
- US $30.00 / box
- 98%
- hebei hongtan Biotechnology Co., Ltd
-
- Ganirelix Acetate
123246-29-7
- US $0.00-0.00 / box
- 99
- Shanghai Affida new material science and technology center
-
- Ganirelix
123246-29-7
- US $10.00 / kg
- 98%
- Hebei Guanlang Biotechnology Co,.LTD